Last Update: May 21, 2024
Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent
ClinicalTrials.gov Identifier:
NCT05301907
Novartis Reference Number:CBAF312A2006
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Survey to be completed independently by HCPs (neurologists treating patients with MS and
MS specialist nurses) and patients/caregivers. The survey- based study is conducting amongst HCPs and patients/caregivers in selected
European countries including Germany, Netherlands, Nordics (Denmark, Sweden), Spain and
Croatia, plus Canada, to evaluate whether HCPs and patients/caregivers receive the
educational materials and to capture their knowledge of specific Mayzent (siponimod)
safety measures.

Multiple Sclerosis
Recruiting
335
Dec 02, 2021
Sep 30, 2024
All
18 Years - (Adult, Older Adult)

Eligibility Criteria

Inclusion Criteria:

Physicians will be considered eligible for the survey if they meet the following
screening criteria:

- Care for relapsing MS (RMS) patients

- Personally prescribed disease modifying therapies to MS patients, and;

- Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.

Nurses will be considered eligible for the survey if they:

- Provide supportive care for RMS patients

- Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS
patient.

Patient inclusion criteria include:

- Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement

Exclusion Criteria:

-

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111